Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6321691 | 0.91 | ALOX5 (0.53) | CYP4F2CYP4A11TDP1CYP4Z1PPARA | |
| SCHEMBL9514885 | 0.90 | CYP4F2 (0.51) | CYP4F2CYP4A11CYP4Z1PPARAPPARG | |
| SCHEMBL16747377 | 0.89 | PPARA (0.53) | CYP4F2CYP4A11TDP1CYP4Z1PPARA | |
| SCHEMBL4425984 | 0.87 | CYP4F2 (0.64) | CYP4F2CYP4A11TDP1CYP4Z1PPARA | |
| SCHEMBL698078 | 0.86 | CYP4F2 (0.55) | CYP4F2CYP4A11TDP1FFAR1MAOA | |
| SCHEMBL1125304 | 0.84 | MAOB (0.46) | CYP4Z1PPARAPPARGMAOAMAOB | |
| SCHEMBL13104077 | 0.83 | CYP4F2 (0.58) | CYP4F2CYP4A11TDP1CYP4Z1PPARA | |
| SCHEMBL879289 | 0.83 | CYP4F2 (0.58) | CYP4F2CYP4A11TDP1CYP4Z1PPARA | |
| SCHEMBL31189319 | 0.82 | CYP4F2 (0.42) | CYP4F2CYP4A11TDP1FFAR1MAOA | |
| SCHEMBL8801649 | 0.82 | CYP4F2 (0.48) | CYP4F2CYP4A11TDP1CYP4Z1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250248975-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2025-08-07 | — | — | US | disclosed |
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | SIONNA THERAPEUTICS INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4396179-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| CN-118201919-A | Indole compounds and methods of use | 健赞公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024054851-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-111491939-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2008131368-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| EP-0684948-B1 | MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME | DIAGNOSTIKFORSCHUNG INST (DE) | 1997-10-22 | — | — | EP | disclosed |
| US-5674467-A | USED IN NMR DIAGNOSIS, RADIODIAGNOSIS OR RADIOTHERAPY | INSTITUT FUR DIAGNOSTIKFORSCHUNG GMBH (DE) | 1997-10-07 | — | — | US | disclosed |
| EP-0684948-A1 | MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME. | DIAGNOSTIKFORSCHUNG INST (DE) | 1995-12-06 | — | — | EP | disclosed |
| WO-1994019352-A1 | MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin (DE) | 1994-09-01 | — | — | WO | disclosed |
| EP-0219308-B1 | 2-SUBSTITUTED QUINOLINES | MERCK FROSST CANADA INC. (CA) | 1991-10-23 | — | — | EP | disclosed |
| EP-0219308-A2 | 2-Substituted quinolines | MERCK FROSST CANADA INC. (CA) | 1987-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | CYP4F2 1768/4885CYP4A11 966/4885TDP1 3316/4885 |
| US-12024531-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | CYP4F2 3818/4885CYP4A11 2998/4885TDP1 1544/4885 |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | CYP4F2 3818/4885CYP4A11 2998/4885TDP1 1544/4885 |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | NR1H2, NR1H3, SREBF1 | CYP4F2 246/4885CYP4A11 113/4885TDP1 2710/4885 |
| US-20250248975-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | CYP4F2 1256/4885CYP4A11 594/4885TDP1 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.